Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin.

Radioiodine ablation (RA) of normal thyroid remnants after thyroidectomy for differentiated thyroid carcinoma improves the sensitivity of subsequent radioiodine scans and serum thyroglobulin measurements for detection of residual thyroid carcinoma. Local cancer recurrences are also lower after RA. One standard preparation for RA involves rendering the patient hypothyroid in order to stimulate endogenous thyrotropin (TSH) secretion and sodium iodide symporter (NIS) activity. An alternative approach is to prescribe thyroxine after thyroidectomy and to stimulate NIS with exogenous recombinant human thyrotropin (rhTSH). This latter approach was used in 10 patients at our medical center. Complete resolution of all visible 131I thyroid bed uptake was achieved in all when follow-up scans were performed 5 to 13 months later. This approach has the potential to successfully ablate thyroid remnants without the need to induce hypothyroidism.

[1]  S. Larson,et al.  Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  S. Larson,et al.  Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[3]  J. Humm,et al.  Thyroid cancer dosimetry using clearance fitting. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R. Weigel,et al.  Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. , 1999 .

[5]  P. Perros Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. , 1999, Journal of endocrinological investigation.

[6]  G. Mariani,et al.  Mapping sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue-dye, and intraoperative gamma-probe. , 2000, Cancer biotherapy & radiopharmaceuticals.

[7]  R. Tsang,et al.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma , 1998, Cancer.

[8]  E. Mazzaferri Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. , 1997, Thyroid : official journal of the American Thyroid Association.

[9]  L. Wartofsky Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma , 1998 .

[10]  M. Burge,et al.  Isolated thyrotropin deficiency secondary to primary empty sella in a patient with differentiated thyroid carcinoma: an indication for recombinant thyrotropin. , 1999, Thyroid : official journal of the American Thyroid Association.

[11]  H. Macapinlac,et al.  Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. , 1998, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[12]  D. Roos,et al.  Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique. , 1999, International journal of radiation oncology, biology, physics.

[13]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.

[14]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[15]  L. Braverman,et al.  Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). , 1994, The Journal of clinical endocrinology and metabolism.

[16]  B. de Keizer,et al.  Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy , 2000, Nuclear medicine communications.

[17]  C. Bal,et al.  Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma , 1996, Cancer.

[18]  E. Molinari,et al.  Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. , 2000, Cancer biotherapy & radiopharmaceuticals.

[19]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.

[20]  B. Ferrell,et al.  Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. , 1997, Thyroid : official journal of the American Thyroid Association.

[21]  J. Shah,et al.  Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 , 2000, Cancer.

[22]  R. Leeper The Effect of 131I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid Carcinoma , 1973 .

[23]  G. Beckett,et al.  Use of recombinant thyrotropin , 2002, The Lancet.

[24]  J. Garber,et al.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.